Alimera Sciences Stock Price, News & Analysis

Alimera Sciences (Nasdaq: ALIM) announced that Rick Eiswirth, President and CEO, will present at the Zooming with LD Micro virtual conference on April 15, 2021, at 11:00 AM ET. The event will include a live Q&A session and offers registered investors opportunities for one-on-one meetings. Alimera focuses on developing prescription ophthalmic treatments for retinal diseases, addressing significant unmet medical needs in aging populations. For more details, visit www.alimerasciences.com.

Alimera Sciences (Nasdaq: ALIM) announced that its President and CEO, Rick Eiswirth, will present at the Benzinga Biotech Small Cap Conference on March 25, 2021, at 12:00 pm ET. The conference will take place from March 24-25, 2021. Investors can view Eiswirth's presentation after registration and request a 1x1 meeting. Alimera is focused on the development of ophthalmic pharmaceuticals for retinal diseases, addressing a significant need in an aging population. For more information, visit www.alimerasciences.com.

Alimera Sciences (Nasdaq: ALIM) announced significant progress in its global expansion strategy with ILUVIEN pricing published in Denmark and Luxembourg. The company received reimbursement approval for the prevention of relapse in non-infectious uveitis from Ireland's largest private health insurers, covering approximately 50% of the country’s covered lives. Despite challenges posed by the COVID-19 pandemic, Alimera reports a consistent positive reception from healthcare professionals regarding ILUVIEN's impact on patients.

Alimera Sciences, a pharmaceutical firm focusing on ophthalmology, announced that President and CEO Rick Eiswirth will present at the Inaugural Emerging Growth Virtual Conference on March 17-18, 2021. Investors can view his presentation on March 17 after registering for the conference. An archived replay will also be accessible on the conference website. Alimera is dedicated to addressing retinal diseases, which often lack effective treatments and significantly impact aging populations. For more information, visit www.alimerasciences.com.

Alimera Sciences (Nasdaq: ALIM) announces that its President and CEO, Rick Eiswirth, will present at the H.C. Wainwright Global Life Sciences Conference on March 9-10, 2021. The presentation will be available on-demand from March 9 at 7:00 am ET for 90 days. Investors can register for the conference to view the presentation and request one-on-one meetings with Mr. Eiswirth. Alimera focuses on developing prescription ophthalmology treatments for retinal diseases, addressing significant unmet needs in this area.

Alimera Sciences, Inc. (Nasdaq: ALIM) reported its financial results for Q4 and FY 2020, revealing consolidated net revenue of $13.8 million for Q4, a 10% increase from Q3 but a 20% decline from Q4 2019. The annual net revenue totaled $50.8 million, reflecting a 6% decrease from 2019. Net losses were $(1.0) million for Q4 and $(5.3) million for the year, compared to $0.5 million income and $(10.4) million loss in 2019, respectively. Adjusted EBITDA was $1.1 million for Q4, down from $2.6 million in Q4 2019, while international net revenue increased by 20% compared to 2019.

Alimera Sciences (NASDAQ: ALIM) has expanded the availability of its ILUVIEN therapy to Finland for treating diabetic macular edema (DME) and non-infectious posterior uveitis (NIPU). This launch marks a strategic step in Alimera's mission to provide long-term treatment solutions, now available in 13 countries. ILUVIEN offers sustained release for up to three years, contrasting with traditional short-term therapies requiring frequent injections. The therapy aims to improve vision while minimizing recurrence and treatment frequency.

Alimera Sciences, Inc. is set to report its fourth quarter and full year 2020 financial results on February 24, 2021, after the market closes. A conference call will take place on February 25, 2021, at 9:00 AM ET, to discuss the financial results and corporate developments. Participants can pre-register for the call or join via dial-in options. A replay will be available for those unable to attend the live session. Alimera focuses on prescription ophthalmic pharmaceuticals for retinal diseases, addressing significant unmet medical needs.

Alimera Sciences, a leader in ophthalmology treatments, announced CEO Rick Eiswirth will present at the Microcap Rodeo Winter Wonderland Conference from February 16-19, 2021. The live presentation is scheduled for February 16, 2021, at 1:00 PM ET and will include a Q&A session. After the live event, the presentation will be available on-demand. Additionally, one-on-one meetings will take place on February 18 and 19, 2021. Alimera focuses on developing treatments for retinal diseases, addressing unmet needs in an aging population.